Analysis of early death in Japanese patients with advanced non-small cell lung cancer treated with nivolumab

In the first 3 months of nivolumab treatment, 38 patients (18.6%) of 201 non-small cell lung cancer patients died (early death). A PS score ≥ 2, pretreatment of CAR > 0.3, and poor response to prior treatment, were risk factors of early death. The major reasons for early death were disease progression and/or immune-related adverse event.

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2yn28dK
via IFTTT